Tiziana Life Sciences (TLSA) said Tuesday the ALS Association has approved its grant application for funding a 20-participant clinical study of two doses of its intranasal foralumab candidate to treat amyotrophic lateral sclerosis.
The company said it will receive the funding as part of the Hoffman ALS Clinical Trial Awards Program.
Terms of the funding weren't disclosed.
Tiziana said it is also evaluating intranasal foralumab in a phase 2a multicenter, dose-ranging study in patients with non-active secondary progressive multiple sclerosis.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。